StockNews.AI
GMED
StockNews.AI
35 days

Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue

1. GMED launched DuraPro™, enhancing surgical navigation capabilities. 2. DuraPro™ aims to revolutionize a $550 million market with oscillating technology. 3. Integration with ExcelsiusGPS™ improves surgical accuracy and safety. 4. Verzera™ drill system complements DuraPro™, aiding bone removal workflows. 5. Expansion signifies GMED's commitment to meet clinical needs in musculoskeletal solutions.

8m saved
Insight
Article

FAQ

Why Bullish?

The launch of innovative products like DuraPro™ and Verzera™ positions GMED to capture significant market share in a $550 million segment, similar to how other companies saw price increases following successful product innovations. For example, Zimmer Biomet experienced a stock surge after releasing their Mako robotic systems, emphasizing the market's positive reception to advanced medical technology.

How important is it?

The article discusses product launches that are critical to GMED's growth strategy, potentially boosting sales and market positioning significantly. The technological advancements outlined are likely to attract surgeon interest, thereby increasing demand.

Why Long Term?

The successful integration of DuraPro™ and Verzera™ into clinical settings can establish GMED as a leader in musculoskeletal innovations over time. A historical precedent can be seen with Intuitive Surgical, which benefited significantly in stock performance as their robotic systems became more widely adopted.

Related Companies

ZMISRGNUVA
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. “Our goal is to revolutionize the $550 million high-speed drill market with the introduction of innovative, next generation oscillation,” said David Hole, president of spine at Globus Medical. “The DuraPro™ oscillating system coupled with navigation enhances the procedural solutions we offer to surgeons to help advance patient care. With its cutting-edge oscillating technology, DuraPro™ helps prevent soft tissue wrapping while retaining a natural sensation akin to that of conventional spinning drills. This system provides surgeons with instruments for efficient, accurate cutting to remove bone, while utilizing oscillating technology to help safeguard delicate tissue. It also features anti-skiving pilot hole drilling; the oscillating nature of the technology allows for drill tips to maintain trajectories without deviating from the starting point, and the brush attachments facilitate thorough discectomies. The versatile system seamlessly integrates with ExcelsiusGPS™ and ExcelsiusHub™ to support accuracy, efficiency and confidence across navigated and non-navigated workflows. “DuraPro™ allows us to navigate around delicate structures with greater confidence during decompressions,” share Drs. Roland Kent and David Glassman of Axis Spine Center in Cour D’Alene, Idaho. “The integration with ExcelsiusGPS™ takes it a step further—providing real-time visualization for accuracy while reinforcing the safety benefits of oscillating technology.” In addition to DuraPro™, Globus Medical launched Verzera™, a navigated high-speed drill system integrated with the ExcelsiusGPS and ExcelsiusHub system. Verzera™ augments existing workflows for surgeons utilizing Globus’ enabling technologies, by allowing them to navigate bone removal during procedures. The expanded Globus Medical Power Portfolio represents the Company’s continued commitment to solving unmet clinical needs and delivering surgeons with added confidence through procedurally integrated technology. Learn more about the Power Portfolio here. About Globus Medical, Inc.Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of Globus Medical contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. Investor contact:Brian Kearns610-930-1800investors@globusmedical.com Media contact:Moran Chavezmedia@globusmedical.com

Related News